Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced/metastatic pancreatic cancer.

Auteurs

Van Cutsem E, Collignon J, Eefsen RL, Ochsenreither S, Zvirbule Z, Ivanauskas A, Arnold D, Baltruskeviciene E, Pfeiffer P, Yachnin J, Magnusson S, Rydberg Millrud C, Sanfridson A, Losic N, Garcia-Ribas I, Tersago D, Awada A

  • Date de publication

    Oktober 2024

  • Type

    Article

  • Tijdschrift

    Clin Cancer Res

  • Naam van de onderzoeker

    AWADA AHMAD HUSSEIN

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Médecine Oncologique

  • PMID

    39385434

  • DOI

    10.1158/1078-0432.CCR-24-0645